Novartis Recognized Among World's Most Sustainable Companies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novartis Recognized Among World's Most Sustainable Companies



Novartis has been named among the 2014 Corporate Knights Global 100. Corporate Knights announced the results of its 2014 Global 100 Most Sustainable Corporations in the World index at the World Economic Forum in Davos. Inclusion in the index is determined using 12 quantitative social, environmental, and governance indicators, including innovation capacity, employee turnover, and leadership diversity.
 
In addition, Novartis has also been listed in the STOXX Global ESG Leaders Index, recognized among the 25 best multinational employers by Great Place to Work Institute, and ranked top pharmaceutical company in Fortune's World's Most Admired Companies.

Source: Novartis

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here